scPharmaceuticals Inc.

NasdaqGS:SCPH Stock Report

Market Cap: US$221.6m

scPharmaceuticals Past Earnings Performance

Past criteria checks 0/6

scPharmaceuticals's earnings have been declining at an average annual rate of -14.7%, while the Pharmaceuticals industry saw earnings declining at 0.4% annually. Revenues have been growing at an average rate of 94.4% per year.

Key information

-14.7%

Earnings growth rate

2.4%

EPS growth rate

Pharmaceuticals Industry Growth6.0%
Revenue growth rate94.4%
Return on equity-655.6%
Net Margin-252.2%
Last Earnings Update30 Jun 2024

Recent past performance updates

Recent updates

Is scPharmaceuticals (NASDAQ:SCPH) Using Too Much Debt?

Jun 27
Is scPharmaceuticals (NASDAQ:SCPH) Using Too Much Debt?

scPharmaceuticals Inc. (NASDAQ:SCPH) Stocks Shoot Up 26% But Its P/S Still Looks Reasonable

Jun 27
scPharmaceuticals Inc. (NASDAQ:SCPH) Stocks Shoot Up 26% But Its P/S Still Looks Reasonable

The scPharmaceuticals Inc. (NASDAQ:SCPH) Full-Year Results Are Out And Analysts Have Published New Forecasts

Mar 16
The scPharmaceuticals Inc. (NASDAQ:SCPH) Full-Year Results Are Out And Analysts Have Published New Forecasts

Is scPharmaceuticals (NASDAQ:SCPH) Using Debt Sensibly?

Nov 25
Is scPharmaceuticals (NASDAQ:SCPH) Using Debt Sensibly?

scPharmaceuticals: Furoscix Approval A Potential Paradigm Shift For Heart Failure Patients

Oct 20

FDA approves scPharmaceuticals Furoscix to treat congestion in heart failure

Oct 10

Does scPharmaceuticals (NASDAQ:SCPH) Have A Healthy Balance Sheet?

Jan 11
Does scPharmaceuticals (NASDAQ:SCPH) Have A Healthy Balance Sheet?

Is scPharmaceuticals (NASDAQ:SCPH) A Risky Investment?

Sep 02
Is scPharmaceuticals (NASDAQ:SCPH) A Risky Investment?

scPharmaceuticals: We Still See A High Probability Of Success For FUROSCIX

Aug 26

Here's What scPharmaceuticals Inc.'s (NASDAQ:SCPH) Shareholder Ownership Structure Looks Like

Mar 09
Here's What scPharmaceuticals Inc.'s (NASDAQ:SCPH) Shareholder Ownership Structure Looks Like

How Many scPharmaceuticals Inc. (NASDAQ:SCPH) Shares Do Institutions Own?

Nov 24
How Many scPharmaceuticals Inc. (NASDAQ:SCPH) Shares Do Institutions Own?

Revenue & Expenses Breakdown

How scPharmaceuticals makes and spends money. Based on latest reported earnings, on an LTM basis.


Earnings and Revenue History

NasdaqGS:SCPH Revenue, expenses and earnings (USD Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
30 Jun 2424-616512
31 Mar 2418-586012
31 Dec 2314-555312
30 Sep 237-504411
30 Jun 234-453611
31 Mar 232-402913
31 Dec 220-372116
30 Sep 220-351618
30 Jun 220-311218
31 Mar 220-291016
31 Dec 210-281016
30 Sep 210-281115
30 Jun 210-311217
31 Mar 210-321218
31 Dec 200-321218
30 Sep 200-351125
30 Jun 200-321025
31 Mar 200-31925
31 Dec 190-33825
30 Sep 190-27817
30 Jun 190-27816
31 Mar 190-291116
31 Dec 180-291416
30 Sep 180-311517
30 Jun 180-311416
31 Mar 180-281215
31 Dec 170-24914
30 Sep 170-22714
30 Jun 170-26814
31 Mar 170-24712
31 Dec 160-24612

Quality Earnings: SCPH is currently unprofitable.

Growing Profit Margin: SCPH is currently unprofitable.


Free Cash Flow vs Earnings Analysis


Past Earnings Growth Analysis

Earnings Trend: SCPH is unprofitable, and losses have increased over the past 5 years at a rate of 14.7% per year.

Accelerating Growth: Unable to compare SCPH's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: SCPH is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (9.5%).


Return on Equity

High ROE: SCPH has a negative Return on Equity (-655.61%), as it is currently unprofitable.


Return on Assets


Return on Capital Employed


Discover strong past performing companies